Crossject Société Anonyme (74C.F)
| Previous close | 2.0000 |
| Open | 2.1100 |
| Bid | 2.0250 x 50000 |
| Ask | 2.2900 x 50000 |
| Day's range | 2.1100 - 2.1100 |
| 52-week range | 1.7420 - 5.7600 |
| Volume | |
| Avg. volume | 101 |
| Market cap | 77.278M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
Extended contract now covers a total of 11 European countries Crossject will receive milestone payments of up to €1 million in total, upon marketing authorizations Crossject will sell ZEPIZURE® to the partner with a markup that is a share of the gross margin Dijon, France May 02, 2024 -530 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has extended the geographic coverage of its 22n
- GlobeNewswire
Crossject reports audited financial results for 2023
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®, reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company’s website. Key financial information as of December 31, 2023 Crossject’s financial results for the year ending December 31, 2023 have
- GlobeNewswire
Crossject trading on Euronext to resume as usual on Wednesday April 3
Dijon, France April 2, 2024 – Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject’s press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations. For that reason, Crossject required Euronext to stop trading. Following Euronext’s standard procedure in such cases,
